Detection of MYC rearrangement in high grade B cell lymphomas: Correlation of MYC immunohistochemistry and FISH analysis

Pathology

Volumn 46, Issue 3, 2014, Pages 211-215

  Lynnhtun, Kyaw ^a   Renthawa, Jasveen ^a   Varikatt, Winny ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Burkitt lymphoma; Diffuse large B cell lymphoma; FISH; Fluorescence in situ hybridisation; IHC; Immunohistochemistry; MYC protooncogene; Unclassifiable

Indexed keywords

MYC PROTEIN; TUMOR MARKER;

ADULT; AGED; B CELL LYMPHOMA; BURKITT LYMPHOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BURKITT LYMPHOMA; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MYC; SENSITIVITY AND SPECIFICITY; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84902168569     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000076     Document Type: Article

References (24)

1. Dominguez-Sola D, Ying CY, Grandori C, et al. Non-transcriptional control by c-Myc. Nature 2007;448:445-51.
2. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001;20:5595-610.
3. Yunis JJ, Mayer MG, Arnesen MA, et al. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989;320:1047-54.
4. Boerma EG, Siebert R, Kluin PM, Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia 2009;23:225-34.
5. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41-9.
6. Slavutsky I, Andreoli G, Gutierrez M, et al. Variant (8;22) translocation in lymphoblastic lymphoma. Leuk Lymphoma 1996;21:169-72.
7. Drach J, Kaufmann H, Urbauer E, et al. The biology of multiple myeloma. Clin Oncol 2000;126:441-7.
8. Swerdlow S, Campo E, Lee Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon; IARC Press, 2008.
9. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large Bcell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology 2008;53:205-17.
10. Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008;22:2226-9.
11. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. ASH Education Book 2009;1:523-31.
12. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-7.
13. Barrans Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360-5.
14. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452-9.
15. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121:2253-63.
16. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3460-7.
17. Pfreundschuh M. Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas. German High-Grade Non-Hodgkin Lymphoma Study Group. J Clin Oncol 2012;30:3433-5.
18. Tapia G, Lopez R, Munoz-Marmol AN, et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology 2011;59:672-8.
19. Green TM, Nielsen O, de Stricker K, et al. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 2012;36:612-9.
20. Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PloS One 2012;7:e33813.
21. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021-31.
22. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
23. Adams JM, Harrs AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8.
24. Leucci E, Cocco M, Onnis A, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 2008;216:440-50.